Cargando…

MicroRNA mimicry blocks pulmonary fibrosis

Over the last decade, great enthusiasm has evolved for microRNA (miRNA) therapeutics. Part of the excitement stems from the fact that a miRNA often regulates numerous related mRNAs. As such, modulation of a single miRNA allows for parallel regulation of multiple genes involved in a particular diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Montgomery, Rusty L, Yu, Guoying, Latimer, Paul A, Stack, Christianna, Robinson, Kathryn, Dalby, Christina M, Kaminski, Naftali, van Rooij, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287936/
https://www.ncbi.nlm.nih.gov/pubmed/25239947
http://dx.doi.org/10.15252/emmm.201303604
_version_ 1782351887053357056
author Montgomery, Rusty L
Yu, Guoying
Latimer, Paul A
Stack, Christianna
Robinson, Kathryn
Dalby, Christina M
Kaminski, Naftali
van Rooij, Eva
author_facet Montgomery, Rusty L
Yu, Guoying
Latimer, Paul A
Stack, Christianna
Robinson, Kathryn
Dalby, Christina M
Kaminski, Naftali
van Rooij, Eva
author_sort Montgomery, Rusty L
collection PubMed
description Over the last decade, great enthusiasm has evolved for microRNA (miRNA) therapeutics. Part of the excitement stems from the fact that a miRNA often regulates numerous related mRNAs. As such, modulation of a single miRNA allows for parallel regulation of multiple genes involved in a particular disease. While many studies have shown therapeutic efficacy using miRNA inhibitors, efforts to restore or increase the function of a miRNA have been lagging behind. The miR-29 family has gained a lot of attention for its clear function in tissue fibrosis. This fibroblast-enriched miRNA family is downregulated in fibrotic diseases which induces a coordinate increase of many extracellular matrix genes. Here, we show that intravenous injection of synthetic RNA duplexes can increase miR-29 levels in vivo for several days. Moreover, therapeutic delivery of these miR-29 mimics during bleomycin-induced pulmonary fibrosis restores endogenous miR-29 function whereby decreasing collagen expression and blocking and reversing pulmonary fibrosis. Our data support the feasibility of using miRNA mimics to therapeutically increase miRNAs and indicate miR-29 to be a potent therapeutic miRNA for treating pulmonary fibrosis.
format Online
Article
Text
id pubmed-4287936
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42879362015-01-12 MicroRNA mimicry blocks pulmonary fibrosis Montgomery, Rusty L Yu, Guoying Latimer, Paul A Stack, Christianna Robinson, Kathryn Dalby, Christina M Kaminski, Naftali van Rooij, Eva EMBO Mol Med Report Over the last decade, great enthusiasm has evolved for microRNA (miRNA) therapeutics. Part of the excitement stems from the fact that a miRNA often regulates numerous related mRNAs. As such, modulation of a single miRNA allows for parallel regulation of multiple genes involved in a particular disease. While many studies have shown therapeutic efficacy using miRNA inhibitors, efforts to restore or increase the function of a miRNA have been lagging behind. The miR-29 family has gained a lot of attention for its clear function in tissue fibrosis. This fibroblast-enriched miRNA family is downregulated in fibrotic diseases which induces a coordinate increase of many extracellular matrix genes. Here, we show that intravenous injection of synthetic RNA duplexes can increase miR-29 levels in vivo for several days. Moreover, therapeutic delivery of these miR-29 mimics during bleomycin-induced pulmonary fibrosis restores endogenous miR-29 function whereby decreasing collagen expression and blocking and reversing pulmonary fibrosis. Our data support the feasibility of using miRNA mimics to therapeutically increase miRNAs and indicate miR-29 to be a potent therapeutic miRNA for treating pulmonary fibrosis. BlackWell Publishing Ltd 2014-10 2014-09-19 /pmc/articles/PMC4287936/ /pubmed/25239947 http://dx.doi.org/10.15252/emmm.201303604 Text en © 2014 miRagen Therapeutics. Published under the terms of the CC BY 4.0 license http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Report
Montgomery, Rusty L
Yu, Guoying
Latimer, Paul A
Stack, Christianna
Robinson, Kathryn
Dalby, Christina M
Kaminski, Naftali
van Rooij, Eva
MicroRNA mimicry blocks pulmonary fibrosis
title MicroRNA mimicry blocks pulmonary fibrosis
title_full MicroRNA mimicry blocks pulmonary fibrosis
title_fullStr MicroRNA mimicry blocks pulmonary fibrosis
title_full_unstemmed MicroRNA mimicry blocks pulmonary fibrosis
title_short MicroRNA mimicry blocks pulmonary fibrosis
title_sort microrna mimicry blocks pulmonary fibrosis
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287936/
https://www.ncbi.nlm.nih.gov/pubmed/25239947
http://dx.doi.org/10.15252/emmm.201303604
work_keys_str_mv AT montgomeryrustyl micrornamimicryblockspulmonaryfibrosis
AT yuguoying micrornamimicryblockspulmonaryfibrosis
AT latimerpaula micrornamimicryblockspulmonaryfibrosis
AT stackchristianna micrornamimicryblockspulmonaryfibrosis
AT robinsonkathryn micrornamimicryblockspulmonaryfibrosis
AT dalbychristinam micrornamimicryblockspulmonaryfibrosis
AT kaminskinaftali micrornamimicryblockspulmonaryfibrosis
AT vanrooijeva micrornamimicryblockspulmonaryfibrosis